Onvansertib Fumarate is a small molecule commercialized by Cardiff Oncology, with a leading Phase II program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 15 clinical trials, of which 5 were completed, 8 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Onvansertib Fumarate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Onvansertib Fumarate is expected to reach an annual total of $177 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Onvansertib Fumarate Overview

Onvansertib fumarate (PCM-075) is under development for the treatment of relapsed or refractory acute myeloid leukemia, pancreatic ductal adenocarcinoma, chronic myelomonocytic leukemia and advanced or metastatic solid tumors including triple negative breast cancer, medulloblastoma, small-cell lung cancer, colorectal cancer, sarcomas, hepatocellular cancer, ampullary cancer, prostate cancer, ovarian cancer, skin cancer and hormone refractory (castration-resistant, androgen-independent) prostate cancer. The drug candidate is administered through the oral route. The drug candidate is a 4,5-dihydro-1H-pyrazolo[4,3- h]quinazoline derivative. The drug candidate is a first in class third generation drug acts by targeting Polo-like-kinase 1 (PLK1). It was also under development for adrenocortical carcinoma (adrenal cortex cancer),non-Hodgkin lymphoma and myelodysplastic syndrome.

Cardiff Oncology Overview

Cardiff Oncology, formerly Trovagene Inc is a clinical-stage biotechnology company that focuses on developing drugs which target cell division (mitosis) using precision cancer medicine (PCM) approach for the treatment of hematologic and solid tumor cancers. The company lead product candidate is Onvansertib (previously known as PCM-075), an oral and adenosine triphosphate (ATP) competitive inhibitor of polo-like kinase 1 (PLK1) enzyme. The company is being developed in combination with chemotherapies and targeted therapeutics for treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic Castration-Resistant Prostate Cancer (mCRPC) and second-line KRAS mutation-metastatic Colorectal Cancer (mCRC). Onvansertib is being evaluated in three clinical trials, namely, TROV-052, TROV-053, and TROV-054. Cardiff Oncology is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2022 (FY2022), an increase of 7.5% over FY2021. The operating loss of the company was US$39.9 million in FY2022, compared to an operating loss of US$28.9 million in FY2021. The net loss of the company was US$38.7 million in FY2022, compared to a net loss of US$28.3 million in FY2021. The company reported revenues of US$0.1 million for the first quarter ended March 2023, a decrease of 35.2% over the previous quarter.

For a complete picture of Onvansertib Fumarate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.